Lenabasum Studied for Refractory Cutaneous Dermatomyositis
Results of phase 2 study suggest clinical benefit and favorable safety profile, warranting further study of lenabasum for DM
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.